Literature DB >> 26131192

The effects of tranexamic acid and 6% hydroxyethyl starch (HES) solution (130/0.4) on postoperative bleeding in coronary artery bypass graft (CABG) surgery.

M Yanartas1, A Baysal2, C Aydın3, Y Ay3, I Kara4, E Aydın1, D Cevirme1, C Köksal1, H Sunar1.   

Abstract

BACKGROUND: The addition of 6% hydroxyethyl starch (HES) into Ringer lactate priming solution may have adverse effects on hemostasis in patients undergoing coronary artery bypass grafting (CABG) with cardiopulmonary bypass (CPB) with or without the use of tranexamic acid.
METHODS: In a prospective, randomized clinical trial, 132 patients were assigned to receive 20 ml/kg of Ringer priming solution with or without tranexamic acid (TA) (Group RS-TA, n=34 and Group RS-noTA, n=32) or 10 ml/kg of 6% HES plus 10 ml/kg of RS priming solution with or without intravenous tranexamic acid (Group HES-TA, n=35 and Group HES-noTA, n=31). Estimated blood loss, chest tube drainage, amount of blood products, hemoglobin, hematocrit, platelet and coagulation parameters were examined before and 24 hour after surgery.
RESULTS: For Group HES with tranexamic acid, when compared to other groups, estimated blood loss, postoperative 24 hour drainage loss and blood product transfusions were less (P=0.023; P=0.003; P=0.001; respectively) and hemoglobin, hematocrit values at 12 and 24 hours after surgery increased in comparison to other groups (P=0.041, P=0.034, P=0.004, P=0.001; respectively). Platelet concentrations were similar between groups (P>0.05).
CONCLUSIONS: In CABG, the administration of tranexamic acid in HES 130/0.4 prime solution study group decreased estimated blood loss and chest tube drainage in comparison to patients receving Ringer prime solution with or without tranexamic acid postoperatively however, no effects on renal functions or postoperative complications were shown.

Entities:  

Keywords:  Hetastarch; cardiac surgery; cardiopulmonary bypass; colloid; crystalloid; hemostasis; renal; tranexamic acid

Year:  2015        PMID: 26131192      PMCID: PMC4484036     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  25 in total

1.  Hydroxyethylstarch and gelatin solutions impair blood coagulation after cardiac surgery: a prospective randomized trial.

Authors:  A Schramko; R Suojaranta-Ylinen; A Kuitunen; P Raivio; S Kukkonen; T Niemi
Journal:  Br J Anaesth       Date:  2010-04-12       Impact factor: 9.166

2.  The effect of intravenous lactated Ringer's solution versus 0.9% sodium chloride solution on serum osmolality in human volunteers.

Authors:  E L Williams; K L Hildebrand; S A McCormick; M J Bedel
Journal:  Anesth Analg       Date:  1999-05       Impact factor: 5.108

3.  Hextend, a physiologically balanced plasma expander for large volume use in major surgery: a randomized phase III clinical trial. Hextend Study Group.

Authors:  T J Gan; E Bennett-Guerrero; B Phillips-Bute; H Wakeling; D M Moskowitz; Y Olufolabi; S N Konstadt; C Bradford; P S Glass; S J Machin; M G Mythen
Journal:  Anesth Analg       Date:  1999-05       Impact factor: 5.108

4.  Comparing the effects of 5% albumin and 6% hydroxyethyl starch 130/0.4 on coagulation and inflammatory response when used as priming solutions for cardiopulmonary bypass.

Authors:  Y S Choi; J K Shim; S W Hong; J C Kim; Y L Kwak
Journal:  Minerva Anestesiol       Date:  2010-05-27       Impact factor: 3.051

5.  Selection of optimal quantity of hydroxyethyl starch in the cardiopulmonary bypass prime.

Authors:  Maha A Ali; Mohamed Saleh
Journal:  Perfusion       Date:  2004-01       Impact factor: 1.972

6.  Is 6% hydroxyethyl starch 130/0.4 safe in coronary artery bypass graft surgery?

Authors:  Joanna Su Min Ooi; Abdul Rahman Mohd Ramzisham; Mohd Dimon Zamrin
Journal:  Asian Cardiovasc Thorac Ann       Date:  2009-08

7.  Rapidly degradable hydroxyethyl starch solutions impair blood coagulation after cardiac surgery: a prospective randomized trial.

Authors:  Alexey A Schramko; Raili T Suojaranta-Ylinen; Anne H Kuitunen; Sinikka I Kukkonen; Tomi T Niemi
Journal:  Anesth Analg       Date:  2009-01       Impact factor: 5.108

8.  Hydroxyethyl starch as a priming solution for cardiopulmonary bypass impairs hemostasis after cardiac surgery.

Authors:  Anne H Kuitunen; Markku J Hynynen; Elina Vahtera; Markku T Salmenperä
Journal:  Anesth Analg       Date:  2004-02       Impact factor: 5.108

9.  Large-dose hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with hydroxyethyl starch 200/0.5 at recommended doses.

Authors:  Stefan-Mario Kasper; Philipp Meinert; Sandra Kampe; Christoph Görg; Christof Geisen; Uwe Mehlhorn; Christoph Diefenbach
Journal:  Anesthesiology       Date:  2003-07       Impact factor: 7.892

10.  Hydroxyethyl starch 6%, 130/0.4 vs. a balanced crystalloid solution in cardiopulmonary bypass priming: a randomized, prospective study.

Authors:  Hasan Alper Gurbuz; Ahmet Baris Durukan; Nevriye Salman; Murat Tavlasoglu; Elif Durukan; Halil İbrahim Ucar; Cem Yorgancioglu
Journal:  J Cardiothorac Surg       Date:  2013-04-08       Impact factor: 1.637

View more
  3 in total

1.  The safety and efficiency of intravenous administration of tranexamic acid in coronary artery bypass grafting (CABG): a meta-analysis of 28 randomized controlled trials.

Authors:  Yanting Zhang; Yun Bai; Minmin Chen; Youfa Zhou; Xin Yu; Haiyan Zhou; Gang Chen
Journal:  BMC Anesthesiol       Date:  2019-06-14       Impact factor: 2.217

2.  Effects of crystalloid and colloid priming strategies for cardiopulmonary bypass on colloid oncotic pressure and haemostasis: a meta-analysis.

Authors:  Anne Maria Beukers; Jamy Adriana Catharina de Ruijter; Stephan Alexander Loer; Alexander Vonk; Carolien Suzanna Enna Bulte
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-08-03

3.  Comparison of the Effects of Ringer's Lactate and 6% Hydroxyethyl Starch 130/0.4 on Blood Loss and Need for Blood Transfusion After Off-Pump Coronary Artery Bypass Graft Cardiac Surgery.

Authors:  Roshani Manwani; Neha Gupta; Shilpa Kanakam; Minal Vora; Krishnan Bhaskaran
Journal:  Cureus       Date:  2021-06-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.